January 5, 2017
What a year. With two Supreme Court decisions and nearly $5 billion in recoveries (among other interesting entries) in 2016’s now-closed books, we can say with certainty that 2016 delivered plenty of False Claims Act (“FCA”) headlines. It is also clear that the U.S. government, state governments, and private whistleblowers (i.e., qui tam relators) continue to press new and aggressive theories of liability under the FCA–with significant success. As recoveries remained high and fraud theories proliferated, 2016 saw the second highest number of FCA lawsuits ever brought in a single year. Looking forward, we have little reason to believe that the government’s haul from FCA matters–or the sheer number of FCA lawsuits–will decline materially next year.
But there are several issues that will continue to be closely watched–and contested–as we head into 2017. Foremost among them is the extent to which the Supreme Court’s 2016 decision in Universal Health Services, Inc. v. United States ex rel. Escobar, 136 S. Ct. 1989 (2016), abrogated existing FCA jurisprudence regarding the statute’s falsity, materiality, and scienter elements. To the government and relators, the case represents a course correction that leaves intact the path to recover on expansive (and often nebulous) theories of liability. For defendants, Escobar requires a sweeping reassessment of the theories and allegations that have allowed plaintiffs to survive the pleading stage–and even prevail–in cases where falsity, materiality, and scienter are not readily apparent. As detailed below, the lower courts are beginning to coalesce around particular readings of Escobar; we will continue to monitor these developments throughout 2017.
Questions also linger about the incoming administration’s impact on FCA enforcement. Many observers inside and outside government have suggested that FCA enforcement may be insulated from more dramatic shifts elsewhere at the U.S. Department of Justice (“DOJ”) because of the FCA’s bipartisan appeal as a tool for returning funds to the government. But, as described below, the incoming administration’s campaign commitment to scrap the Patient Protection and Affordable Care Act (“ACA”), if implemented, could unwind recent changes to the FCA’s statutory language and scope, with potentially important consequences. Meanwhile, certain industries may hope for less aggressive enforcement–at least from the government–in the next four years. And individuals facing liability as part of the DOJ’s renewed emphasis on personal accountability under the so-called Yates Memorandum would welcome a reprieve from the Obama administration’s aggressive enforcement priorities.
This update first details enforcement activity under the FCA during the Fiscal Year ending September 30, 2016. In the hopes of distinguishing trends from aberrations, we break down the past year’s enforcement data, focusing on the key theories underlying, and the industries targeted in, the government’s nearly $5 billion recovery haul, and then survey the key settlements and judgments in the last six months. We then turn to the mostly quiet legislative front, summarizing the past year’s developments and analyzing potential ACA-related changes that may come to pass in 2017. Finally, we analyze the developments in FCA jurisprudence during the latter half of 2016. Please refer to our 2016 Mid-Year False Claims Act Update (“2016 Mid-Year Update”) for our assessment of the legislative and case law developments during the first half of the year.
As always, Gibson Dunn’s recent publications on the FCA may be found on our Website, including in-depth discussions of the FCA’s framework and operation along with practical guidance to help companies avoid or limit liability under the FCA. And, of course, we would be happy to speak with you about these developments.
The federal government recovered more than $4.7 billion in civil settlements and judgments under the FCA during the 2016 fiscal year, the third-highest amount on record. There were also more than 800 new FCA cases filed in 2016, the second-highest number of FCA cases in any single year on record. All in all, 2016 was the seventh consecutive year in which the government recovered over $3 billion and where there were at least 700 new FCA matters. Below, we discuss the qui tam activity driving these remarkably high numbers and the industries that were most significantly affected.
Last year, we reported on the notable fact that the government recovered a record $1.2 billion in qui tam suits where the government declined to intervene. This may well have been an aberration. Historically, the government’s decision on intervention has been strongly correlated with the potential for significant recoveries. And in 2016, recoveries in declined cases returned to a figure consistent with years past ($105 million). That figure represented approximately 2% of all federal recoveries in 2016–a stark contrast to 2015, where cases in which the government declined to intervene accounted for a whopping 32% of all federal recoveries in 2015.
This past year’s figure does not result from any lack of effort. Keeping with the trends since the 1986 amendments to the FCA, the vast majority–about 83%–of new FCA cases filed in fiscal year 2016 were initiated by a whistleblower (702 out of 845). Although consistent with recent years, this marks a dramatic increase since Congress amended the FCA in 1986: in the first five years after the amendments, only about one-quarter of FCA cases were qui tam cases. Yet, whistleblowers have now brought more than 11,000 qui tam cases since 1986–70% of the total.
The chart below demonstrates both the increase in overall FCA litigation activity since 1986 and the distinct shift from largely government-driven investigations and enforcement to qui tam-initiated lawsuits. After two years of declines in the overall number of cases, 2016’s total jumped up to a near-record total:
The government chooses to intervene in about 20% of FCA cases. But, as noted above, that sliver of the overall total of FCA cases resulted in the vast majority of recoveries for the federal government in 2016:
Recoveries from health care and life sciences companies continued to make up the lion’s share of the total of FCA recoveries, as the government recovered $2.5 billion from entities in the health care industry. But after a relatively quiet 2015 for FCA cases involving financial institutions, the DOJ also obtained more than $1.6 billion from the financial industry in 2016 thanks to reinvigorated enforcement of alleged mortgage-related fraud.
Just as in 2015, 55% of all federal FCA recoveries came from the health care industry (including life sciences companies) in 2016. The typical health care FCA case involves allegations that a defendant defrauded federal health care programs, such as Medicare, Medicaid, and TRICARE, which provides health care to members of the armed services and their dependents. Since January 2009, the DOJ has recovered $19.3 billion for purported health care fraud under the FCA. Just shy of $2.6 billion of that total came in fiscal year 2016.
That substantial sum represented a significant rebound from recoveries in each of the preceding three years, thanks in part to another round of large-value settlements from a handful of companies. For example, a branded pharmaceutical maker paid $413 million to the federal government after it allegedly reported falsely inflated prices for two of its drugs to Medicaid, thereby decreasing rebate payments it was required to make to Medicaid that were pegged to those prices. Another maker of branded drugs settled with the government for $390 million–including nearly $307 million paid to the federal government–to resolve allegations that it paid kickbacks to pharmacies that agreed to recommend two of the company’s drugs.
Federal regulators were active on this front during the past year. In its Spring 2016 Semiannual Report to Congress, the Department of Health and Human Services Office of Inspector General (“HHS OIG”) reported that it commenced 379 civil actions (including but not limited to FCA actions) in the first half of the 2016 fiscal year, far in excess of the 320 it commenced during the same period in 2015. HHS OIG also reported expected recoveries of approximately $2.8 billion, including about $2.2 billion in “investigative receivables.” Both of these figures are more than 50% greater than the comparable figures from just a year ago.
It will come as no surprise that the Anti-Kickback Statute (“AKS”) and the Stark Law lurked behind many of the FCA recoveries in the health care industry this past year. The AKS prohibits giving or offering–and requesting or receiving–any form of payment in exchange for referring a product or a service that is covered by federally funded health care programs. The Stark Law prohibits physicians from referring Medicare patients to a provider with which the physician has a financial relationship. Among other noteworthy settlements in 2016, the DOJ entered into a settlement with a laboratory testing company for nearly $260 million after it allegedly violated the AKS and the Stark Law by allegedly billing for unnecessary testing and bribing physicians to refer tests to the company.
FCA recoveries from hospitals and hospital systems have lagged behind those from pharmaceutical, medical device, and outpatient clinics in recent years. However, in 2016, a large chain of hospitals paid more than $360 million after the government alleged that it paid kickbacks to physicians.
Recoveries from government contracting firms dropped in 2016 as compared to recent years (down to $122 million). Of that amount, $82.6 million came from the government’s settlement with an energy exploration company of allegations that the company concealed unsafe drilling habits, leading to an oil spill. The government alleged that this constituted an FCA violation because of billings related to the exploration company’s lease of the land on which it drilled from the Department of the Interior.
In what could be the beginning of a trend in the next administration, the DOJ recovered about $50 million for alleged violations of customs regulations that impose duties on certain imported goods. For example, a Texas company and a California company both paid $15 million for allegedly evading duties on Chinese furniture. Given the rhetoric on trade and imports that pervaded the presidential campaign, this type of case seems likely to continue to gain steam in 2017.
In 2014, the government recovered massive amounts of money in FCA cases against financial institutions that allegedly contributed to the financial crisis through their mortgage lending and underwriting practices. In 2015, recoveries from the financial industry declined by about 90% from their 2014 high of more than $3.1 billion. But anyone who believed that the government was no longer pursuing financial institutions for mortgage-related practices in the lead-up to the financial crisis was sorely mistaken. Financial-industry FCA recoveries more than quadrupled in 2016, up to $1.6 billion.
As noted above, FCA settlements and judgments resulted in more than $4.7 billion in recoveries for the government this year. We summarize below a number of notable settlements and judgments announced during the past six months (notable settlements and judgments from the first half of the year were covered in our 2016 Mid-Year Update), including in the health care and life sciences industries, government procurement and defense industries, and the financial industry. These cases provide specific examples of the industries the government has targeted, as well as the theories of liability that the government and relators have advanced.
Notably, in the first full year after it issued the Yates Memorandum, which promised a more aggressive approach to individual accountability, the DOJ also secured millions of dollars in recoveries from individuals, including at least ten doctors and health care industry executives. Several of these cases are also highlighted below.
In light of the November 2016 election, it is not surprising that the second half of 2016 was relatively quiet on the legislative front. Although there was no new legislation at the federal level, the Department of Justice’s interim final rule increasing maximum penalties for FCA violations took effect on August 1, 2016. Under the rule, the maximum penalties jumped from $11,000 to $21,563 per claim. The rule applies to penalties assessed after August 1, 2016, whose associated violations occurred after November 2, 2015 and, as discussed in our 2016 Mid-Year Update, may result in an uptick in Eighth Amendment and Due Process challenges to judgments, particularly when the amount awarded in penalties dwarfs the damage to the government.
If, as expected, the new Congress introduces legislation to repeal and/or replace the ACA, consistent with the President-elect’s campaign promise, the new year may bring a flurry of FCA-related activity at the federal level. We address below the potential impact of a repeal on those provisions of the ACA that modified the FCA.
At the state level, legislative activity was also quiet, with no significant legislative developments since our 2016 Mid-Year Update.
The President-elect has promised to repeal the ACA within his first 100 days in office. Although many Congressional leaders also have pledged to repeal the ACA, it is difficult to predict precisely how Congress will handle the ACA. The significant questions that remain regarding the extent to which Congress will repeal–and, perhaps, replace–the ACA implicate the components of the FCA that were amended by the ACA.
In particular, the ACA modified the FCA’s “public disclosure bar” in several respects. The ACA removed any reference to “jurisdiction” from the public disclosure bar, a shift which several courts have interpreted to mean that the bar is no longer jurisdictional in nature. See, e.g., United States ex rel. Moore & Co., P.A. v. Majestic Blue Fisheries, LLC, 812 F.3d 294, 299–300 (3d Cir. 2016). The ACA also provided the government discretion to oppose the dismissal of qui tam actions where the allegations are based on public disclosures. 31 U.S.C. § 3730(e)(4). Further, the ACA narrowed the definition of “public” disclosures to encompass only federal criminal, civil, or administrative disclosures, meaning that relators can base qui tam lawsuits on disclosures from state and local government sources, unless the information is also disclosed in the news media or another source encompassed by the statutory language. 31 U.S.C. § 3730(e)(4)(A)(i)–(iii). The ACA also modified the standard for a relator to qualify as an “original source.” Rather than requiring the relator to have “direct and independent knowledge” of the alleged fraud, the ACA eliminated the “direct” knowledge requirement, and instead required “knowledge that is independent of and materially adds to the publicly disclosed allegations or transactions.” 31 U.S.C. § 3730(e)(4)(C).
Aside from those procedural amendments, the ACA altered the FCA in ways that were particularly important to Medicare and Medicaid providers. First, the ACA clarified the 60-Day Rule established under the Fraud Enforcement and Recovery Act of 2009 (“FERA”), which requires payback of Medicare and Medicaid overpayments within 60 days of identification. 42 U.S.C. § 1320a-7k(d). The failure to return government overpayments can lead to potential FCA liability under a “reverse false claims” theory pursuant to 31 U.S.C. § 3729(a)(1)(G). Second, the ACA also provided that any claim submitted in violation of the AKS constitutes a false and fraudulent claim for purposes of the FCA. Further, the ACA relaxed the intent requirement such that the government can establish a violation of the AKS without showing that a defendant either knew about the statute’s specific prohibitions or intended to violate the statute. 42 U.S.C. § 1320a-7b(h).
A full repeal of the ACA would have the effect of eliminating all of these provisions. However, with Congress still undecided about how to address the ACA, the amendments relevant to FCA enforcement remain intact.
There was very little legislative activity at the state level in the second half of 2016. But that activity may pick up as a result of a September 2016 announcement by the CMS that states should amend their false claims acts in the next two years to mirror the increased civil penalties available under federal law. States that do not take this action may be deemed by the DOJ and HHS OIG to be less effective than the federal FCA in facilitating qui tam actions and thereby lose the ability to increase by 10% their share of recoveries in cases that prosecute Medicaid fraud.
On May 2, 2016, the Louisiana Senate voted against legislation introduced in 2014 to create a broader Louisiana False Claims Act (S.B. 327). However, on May 3, 2016, the bill was returned to the calendar and may be called for further consideration at a later time. Currently, Louisiana has a false claims act circumscribed to claims related to funds for medical care.
Additionally, HHS OIG has determined that the Nevada False Claims Act and amended Washington Medicaid Fraud False Claims Act are compliant with Debt Recovery Act (“DRA”) requirements and are at least as robust as the federal FCA. HHS OIG has yet to announce whether Maryland’s expanded False Claims Act, which became effective in 2015, and Wyoming’s False Claims Act, enacted in 2013, meet DRA requirements.
As for several items that we mentioned in previous updates:
The Supreme Court’s June 2016 Escobar decision drove significant developments in FCA jurisprudence during the second half of the past year. But, as discussed below, the federal courts also handed down noteworthy cases addressing other aspects of the FCA during the last six months.
As we reported in our 2016 Mid-Year Update, the Supreme Court’s landmark Escobar decision reshaped the legal landscape in FCA cases. Indeed, the Court both affirmed the viability of the “implied false certification” theory of liability under certain circumstances and sharpened the FCA’s “demanding” materiality standard.
Yet, like many Supreme Court decisions, Escobar does not answer all questions. Thus, in the wake of Escobar the lower courts have grappled with the Supreme Court’s opinion. Two hotly litigated issues have come to the forefront in these cases: (1) the requirements a plaintiff must meet to advance a viable “implied false certification” theory and (2) the proper application of Escobar’s interpretation of the FCA’s materiality standard. We explore the key cases addressing these issues below, and we will closely monitor these and other Escobar-related issues as they develop in the upcoming year.
The Supreme Court stated in Escobar that an “implied certification” theory can provide a basis for liability under the FCA where (1) “the claim does not merely request payment, but also makes specific representations about the goods or services provided,” and (2) “the defendant’s failure to disclose noncompliance with material statutory, regulatory, or contractual requirements makes those representations misleading half-truths.” 136 S. Ct. at 2001 (emphasis added). Since then, the lower courts have reached different conclusions as to the precise circumstances under which a relator may pursue an implied certification theory.
Most courts have imposed a strict test, requiring the FCA plaintiff to show the defendant made specific misleading representations about the goods or services provided to be liable based on an implied false certification theory. See, e.g., United States ex rel. Tessler v. City of N.Y., No. 14-CV-6455, 2016 WL 7335654, at *4 (S.D.N.Y. Dec. 16, 2016); United States v. Crumb, No. 15-0655, 2016 WL 4480690, at *12 (S.D. Ala. Aug. 24, 2016); United States ex rel. Beauchamp v. Academi Training Ctr., Inc., No. 1:11-CV-371, 2016 WL 7030433, at *3 (E.D. Va. Nov. 30, 2016). As these courts have observed, imposing liability in the absence of a sufficiently “specific” misrepresentation about the goods or services provided “would result in an ‘extraordinarily expansive view of liability’ under the FCA, a view that the Supreme Court rejected in Escobar.” Tessler, 2016 WL 7335654, at *4 (citing Escobar). Under this reading of Escobar, courts have not hesitated to dismiss cases where the relator fails to identify specific misrepresentations. See, e.g., Tessler, 2016 WL 7335654, at *4; cf. New York ex rel. Khurana v. Spherion Corp., No. 15-CV-6605, 2016 WL 6652735, at *15 (S.D.N.Y. Nov. 10, 2016) (dismissing New York False Claims Act claim under Escobar on this basis).
In October, the Seventh Circuit addressed Escobar’s impact on the implied false certification theory, concluding that a relator must prove the defendant made specific, misleading representations in connection with a claim for payment. In United States v. Sanford–Brown, Ltd., the Seventh Circuit reconsidered an earlier opinion affirming summary judgment in favor of the defendant, after the Supreme Court vacated and remanded the case in light of Escobar. 840 F.3d 446–47 (7th Cir. 2016). There, following Escobar, the Seventh Circuit held that an implied false certification theory can only be a basis for liability where (i) “the claim does not merely request payment, but also makes specific representations about the goods or services provided” and “the defendant’s failure to disclose noncompliance with material statutory, regulatory, or contractual requirements makes those representations misleading half-truths.” Id. at 447. The court once again affirmed summary judgment for the defendant, finding that the relator had offered no evidence that the defendant had made “any representations at all,” let alone a misleading one. Id. (holding that “bare speculation that [a defendant] made misleading representations is insufficient”).
Among the courts that have strictly construed Escobar, several have concluded that use of billing codes that correspond to particular services, procedures, or individuals with certain qualifications are sufficiently “specific” representations, if false, to state a claim. See Crumb, 2016 WL 4480690, at *13 (Medicare and Medicaid billing codes); United States ex rel. Lee v. N. Adult Daily Health Care Ctr., No. 13-CV-4933, 2016 WL 4703653, at *11 (E.D.N.Y. Sept. 7, 2016) (Medicaid billing codes); Beauchamp, 2016 WL 7030433, at *3 (codes corresponding to jobs restricted to those with specific qualifications). By contrast, at least one court has held that general allegations regarding representations that the defendant complied “with applicable implementing federal, state, and local statutes, regulations, [and] policies,” fail to represent anything specific about the good or services. See Tessler, 2016 WL 7335654, at *4.
A minority of courts has embraced a less restrictive reading of Escobar, rejecting the notion that an implied certification theory requires specific misleading representations. For example, in Rose v. Stephens Institute, the court rejected the argument “that Escobar establishes a rigid” test for falsity “that applies to every single implied false certification claim.” No. 09-CV-05966, 2016 WL 5076214, at *5 (N.D. Cal. Sept. 20, 2016). Reasoning that the Supreme Court left the door open by limiting its holding to “at least” the circumstances before it in Escobar and by expressly declining to “resolve whether all claims for payment implicitly represent that the billing party is legally entitled to payment,” the court held that a relator can state an implied false certification claim without necessarily identifying a “specific” representation that was a “misleading half-truth” in any claim. Id. The court declined, however, to elaborate on what such a claim might look like because it found that the relator had identified a specific representation–in the form of a representation that the defendant was “eligible” to receive the funds for which it was seeking reimbursement. That representation, according to the court, would be a misleading half-truth if, as the plaintiff alleged, the defendant was not in compliance with applicable regulations (and therefore, ineligible to receive payment). Id.
A magistrate judge from the Western District of New York also reached the same conclusion. United States ex rel. Panarello v. Kaplan Early Learning Co., No. 11-CV-00353, Dkt. No. 96, at 8–10 (W.D.N.Y. Nov. 14, 2016). There, the plaintiff alleged that the defendant violated the FCA by submitting claims for work performed by workers who were not paid the government’s prevailing wage requirements. The magistrate judge accepted relator’s theory that the defendant had falsely certified that it had complied with those wage requirements simply by making a claim for payment, reasoning that Escobar does not require specific representations in every implied false certification claim. Id. at 8–9. The court reached this conclusion even as it acknowledged that the claims contained no payment codes (and did not even make any mention of the labor requirements), and thus lacked any “specific” representations. Id. The magistrate judge’s opinion is presently under consideration by the district court.
Although most federal appellate courts have not yet weighed in on the issue, we expect that more will begin to do so in this coming year. The Rose court, for example, subsequently certified its decision on this issue for interlocutory appeal to the Ninth Circuit. 2016 WL 6393513, at *1 (N.D. Cal. Oct. 28, 2016). Similarly, in Panarello, the magistrate judge recommended that the question of whether “specific” representations are required to state an implied certification claim be certified for interlocutory appeal to the Second Circuit, although that issue remains pending before the district court. No. 11-CV-00353, Dkt. No. 96, at 9 (W.D.N.Y. Nov. 14, 2016).
In Escobar, the Supreme Court not only adopted the implied certification theory in some circumstances, but also reframed the FCA’s materiality standard as a question of whether a violation of the specific statute, regulation, or requirement at issue would actually have affected the government’s decision to pay for a claim had it known of the alleged noncompliance. 136 S. Ct. at 1996. In so doing, the Court made clear that whether the particular statutory, regulatory or contractual requirement at issue is specifically labeled a condition of payment remains relevant, but is not dispositive of its materiality, because it is not enough that the government merely have the option not to pay a claim. Id. The Court also stated that the FCA’s materiality requirement is “demanding” and “rigorous.” Id. at 2003–2004 n.6.
Since Escobar, courts have reached differing conclusions as to the decision’s impact on the FCA’s materiality analysis. Several courts have interpreted Escobar as now requiring plaintiffs to plead that: (i) the government either actually does not pay claims that involve violations of the statute or regulation at issue, or (ii) the government was unaware of the violation but “would not have paid” the claims at issue “had it known of” the alleged violations. See, e.g., United States ex rel. Southeastern Carpenters Reg’l Council v. Fulton County, Georgia, No. 1:14-CV-4071, 2016 WL 4158392, at *8 (N.D. Ga. Aug. 5, 2016); Knudsen v. Sprint Commun. Co., No. C13-04476, 2016 WL 4548924, at *14 (N.D. Cal. Sept. 1, 2016); Lee, 2016 WL 4703653, at *12.
In one of the first appellate court decisions on the issue, the Seventh Circuit held that a relator must provide “evidence that the government’s decision to pay” a claim “would likely or actually have been different had it known of [the defendant’s] alleged noncompliance” with the statute, rule, or regulation at issue. Sanford–Brown, 840 F.3d at 447. The court affirmed summary judgment for the defendant, concluding that the alleged noncompliance was not material to the government’s decision to pay claims because the government had “already examined” the alleged misconduct “multiple times over and concluded that neither administrative penalties nor termination was warranted.” Id. at 447–48.
Similarly, in a case discussed in further detail below, the First Circuit concluded that allegations that a defendant’s purported misconduct “could have” influenced “the government’s payment decision” failed to satisfy the “demanding” materiality standard set by Escobar. United States ex rel. D’Agostino v. ev3, Inc., No. 16-1126, — F.3d —, 2016 WL 7422943, at *5 (1st Cir. Dec. 23, 2016). There, in holding the relator had not adequately alleged materiality, the First Circuit also relied on the fact that the government “ha[d] not denied reimbursement” for the claims at issue (nor had it taken any other regulatory actions) despite having been made aware of the allegations of the defendant’s fraudulent conduct six years earlier. Id. In this regard, D’Agostino appears to be somewhat in tension with the First Circuit’s opinion on remand in Escobar, discussed below, in which a different panel of the court distinguished the government’s mere awareness of alleged misconduct from actual knowledge that the misconduct occurred, holding that a relator could still satisfy the materiality requirement despite evidence of the former.
And some courts have even gone further, interpreting Escobar‘s “demanding” materiality standard as requiring a relator’s complaint to “explain why” the government would not have paid claims at issue had it known of the alleged violation, as opposed to simply alleging that the government would not have paid. United States ex rel. Dresser v. Qualium Corp., No. 5:12-CV-01745-BLF, 2016 WL 3880763, at *6 (N.D. Cal. July 18, 2016) (emphasis added); United States ex rel. Scharff v. Camelot Counseling, No. 13-cv-3791, 2016 WL 5416494, at *8–9 (S.D.N.Y. Sept. 28, 2016) (granting motion to dismiss, in part, because relator did not “explain why the purportedly fraudulent conduct was material to the payment of reimbursements”).
On the other hand, some courts have applied a more lenient standard of materiality, in spite of the Court’s language in Escobar. Under this more lenient standard, alleged violations may still be material even where the government takes no action despite being aware of the alleged violations. In Rose, for example, the court denied the defendant summary judgment as to materiality even though defendant argued that the government had “continued to pay [claims] despite having knowledge of the allegations in this case,” and had enforced compliance with the regulation at issue in the past largely by requiring corrective actions or imposing fines rather than by revoking payment. 2016 WL 5076214, at *4. The court reasoned that “[n]othing in Escobar suggests that actions short of a complete revocation of funds are irrelevant to the court’s materiality analysis” and found that a jury could conclude that the alleged noncompliance was material because it was “‘capable of influencing’ the government’s payment decisions” even though it apparently had not done so in the past. Id. at *7 (quoting 31 U.S.C. § 3729(b)(4)). Further clarity on this issue appears to be on the horizon as the district court certified this issue as part of the interlocutory appeal to the Ninth Circuit. Rose, 2016 WL 6393513, at *1.
Decisions from two circuit courts in which relators have been able to satisfy the “demanding” materiality standard also underscore the continued importance of “conditions of payment” and participation, even after Escobar‘s admonition that evidence of conditions of payment is not “automatically dispositive” of materiality. 136 S. Ct. at 2003.
The First Circuit, on remand in Escobar, concluded that the relators’ bare allegation that the government “would not have paid” the allegedly false claims at issue “had it known of the [alleged] violations” was sufficient to establish materiality. United States ex rel. Escobar v. Universal Health Servs., Inc., 842 F.3d 103, 111 (1st Cir. 2016). The First Circuit also relied in part on the fact that the allegedly violated regulatory requirements were “sufficiently important to influence the behavior” of the government in deciding whether to pay the claims because they are conditions of payment, indicating that whether a regulation is a condition of payment may remain important even after Escobar. Id. at 110. The First Circuit also rejected the defendant’s argument that the government continued to pay claims despite being aware of the alleged regulatory noncompliance, holding that “mere awareness of allegations concerning noncompliance with regulations” was not enough to show the violations were immaterial. Id. at 112. The court left the door open, however, to the notion that evidence of the government’s payment despite its “knowledge of actual noncompliance” with the regulation at issue (as opposed to mere awareness of allegations of noncompliance) could be enough to demonstrate a violation is not material. Id.
The Eighth Circuit reached a similar conclusion on summary judgment in another case remanded for reconsideration in light of Escobar. See United States ex rel. Miller v. Weston Educ., Inc., 840 F.3d 494, 504 (8th Cir. 2016). Miller involved allegations that the defendant violated the FCA by fraudulently inducing the Department of Education to provide educational funding under Title IV of the Higher Education Act of 1965, by allegedly falsely promising to comply with student recordkeeping requirements. Id. at 497. Before Escobar, the district court granted summary judgment to the defendant, holding that the alleged noncompliance was immaterial. Id. at 505. The Eighth Circuit reversed that decision, reasoning that the government viewed the recordkeeping requirement as material because it was a condition of participation in Title IV funding. The Supreme Court vacated and remanded that opinion for reconsideration in light of Escobar.
On remand, the Eighth Circuit doubled down on its denial of summary judgment on materiality, again relying on evidence that the government conditioned participation in Title IV programs on compliance with the regulatory recordkeeping requirement. Id. at 504. The court held under Escobar, “a false promise to comply with express conditions is material if it would affect a reasonable government funding decision or if the defendant had reason to know it would affect a government funding decision.” Id. at 504. Applying this standard, the Eighth Circuit held that the government’s repeated conditioning of participation in Title IV funding programs on compliance with the recordkeeping regulation in the statute and elsewhere was sufficient evidence to demonstrate materiality, even as it acknowledged that “conditioning is not ‘automatically dispositive’ of materiality.” Id. (quoting Escobar, 136 S. Ct. at 2003).
The Supreme Court’s foray into the FCA this year was not limited to Escobar–the Court also considered whether a violation of the FCA’s seal requirement mandates dismissal of a relator’s complaint. The FCA provides that a complaint shall be kept under seal for a statutorily mandated period, but is silent as to the result of a violation of that provision, which had led the circuit courts to impose varying consequences, including dismissal, for such a violation. 31 U.S.C. § 3730(b)(2).
On December 6, 2016, in State Farm Fire & Casualty Co. v. United States ex rel. Rigsby, a unanimous Court held that “a seal violation does not mandate dismissal.” 137 S. Ct. 436, 438 (2016). In Rigsby, the relators’ counsel violated the seal provision by e-mailing a sealed filing to several journalists. Id. at 441. The sealed filing disclosed the qui tam complaint and the underlying allegations that an insurer submitted false claims by misclassifying wind damage as flood damage in order to shift insurance liability to the government. Id. Although none of the media outlets revealed the existence of an FCA complaint, each published the underlying allegations of fraud. Id. The relators also met with a Congressman who spoke publicly about the purported fraud, but similarly did not disclose the existence of the FCA suit. Id.
In determining that a seal violation does not necessitate dismissal, the Supreme Court relied on the text and purpose of the FCA. The Court explained that Congress mandated automatic dismissal for certain violations of the FCA, but did not do so for violations of the statute’s seal provision. Id. at 443. As such, the Court decided not to read an automatic consequence of dismissal into the statute. Id. The Court also reasoned that because the “seal requirement was intended in main to protect the Government’s interests,” a rule mandating automatic dismissal for violations would be unduly harsh and undermine the very interests the provision was meant to protect. Id.
The Court declined, however, to resolve the circuit split over the proper test for deciding whether dismissal is warranted for a seal violation. The Fifth and Ninth Circuits employ a three-part test, balancing (1) the actual harm to the Government, (2) the nature of the violations, and (3) evidence of bad faith. United States ex rel. Lujan v. Hughes Aircraft Co., 67 F.3d 242, 245–46 (9th Cir. 1995); United States, ex rel., Rigsby v. State Farm Fire & Cas. Co., 794 F.3d 457, 470–71 (5th Cir. 2015), aff’d 137 S. Ct. 436. The Second and Fourth Circuits employ an “incurable frustration” test that looks to whether the disclosure incurably frustrates four relevant interests of the FCA: (1) allowing the government time to investigate and decide whether to intervene; (2) protecting defendants’ reputations from meritless actions; (3) protecting defendants from having to answer complaints without knowing whether the government or relators will pursue the litigation; and (4) incentivizing defendants to settle to avoid the unsealing of a case. See United States ex rel. Pilon v. Martin Marietta Corp., 60 F.3d 995, 998–99 (2d Cir. 1995) (discussing interests that can be “incurably frustrated” due to seal violation); Smith v. Clark/Smoot/Russell, 796 F.3d 424, 430 (4th Cir. 2015) (following Pilon). Although the Supreme Court noted the factors in the three-part test “appear to be appropriate,” it went no further, stating that it was “unnecessary to explore” the issue until “later cases.” Rigsby, 137 S. Ct. at 444.
Even though the Court did not mandate automatic dismissal of qui tam suits for seal violations, FCA defendants can take solace in the fact that the Supreme Court at the least left lower courts with the discretion to dismiss cases where the seal has been violated, depending on the circumstances. And the Court may very well address what it considers to be the proper test for such a determination in the future.
The First Circuit’s decision in D’Agostino, discussed above, is also notable in that it effectively forecloses alleged fraud perpetrated on the FDA as a basis for FCA liability, with the potential exception of where FDA has actually withdrawn pre-market approval of a medical device based on such fraud. 2016 WL 7422943, at *5. The relator in D’Agostino predicated his FCA claim on allegations that the defendants had made fraudulent misstatements in seeking pre-market approval to FDA for the defendant’s medical device, including that the defendants allegedly disclaimed uses for the device they later pursued, overstated the training they would provide for the device, and omitted critical safety information from the information provided to FDA. Id. at *4–5. According to the relator, FDA would not have approved of the device had it known of the fraudulent statements and, thus the statements ultimately led to a different government agency’s payment of claims for use of that device (which that agency would not have done but for the FDA’s pre-market approval). Id. at *5.
The First Circuit definitively rejected the relator’s fraud on the FDA theory of FCA liability. First, the court reasoned that the relator did not allege that the purported misrepresentations “actually cause[d] the FDA to grant approval it otherwise would not have granted” and, therefore, that he had not demonstrated the required causation between the alleged false statements and disbursement of government funds for the device. Id. at *4–6. Indeed, the court observed that FDA had not withdrawn its pre-market approval of the device, nor had it taken any other action (such as imposing post-approval requirements or suspending approval), despite having been aware of the alleged fraudulent statements for six years. Id. at *6. Second, the Court invoked important policy justifications for its holding, recognizing that “[t]o rule otherwise would be to turn the FCA into a tool with which a jury of six people could retroactively eliminate the value of FDA approval and effectively require that a product largely be withdrawn from the market even when FDA itself sees no reason to do so.” Id. In addition to unjustifiably allowing private parties to override FDA rulings, the First Circuit recognized such a course would be fraught with practical problems, such as deterring new device approval applications, and requiring courts to attempt to determine whether or not “FDA would not have granted approval but for the fraudulent representations” made by the applicant. Id.
Though the First Circuit’s decision reins in future use of fraud-on-FDA theory in the FCA context, the decision leaves open the possibility that such a theory could potentially support a viable FCA claim where FDA had, in fact, made the decision to withdraw its approval of a device after discovering fraud perpetrated during the pre-market approval process. Id. The court, however, expressly declined to resolve whether a relator would be able to state a viable FCA theory under those circumstances. Id.
One issue that has been the subject of many cases over the last several years is what a plaintiff must plead to satisfy Rule 9(b)’s particularity requirement in an FCA case, and therefore survive a motion to dismiss. There have been at least two interesting developments on this front over the last six months relating to: (1) plaintiffs’ attempts to use statistical evidence to satisfy their pleading burden, and (2) whether and when Rule 9(b)’s particularity requirements should be relaxed in certain circumstances.
Recognizing that it can be difficult for some plaintiffs to plead actual facts demonstrating that claims submitted by defendants to the government are false on their face, plaintiffs (primarily relators) have begun regularly attempting to plead “falsity” through statistical sampling. Relators attempt to show that although they cannot allege that a claim submitted to the government is false by comparing the content of the claim to actual facts, they claim the totality of background facts show statistically that it is likely that the statements made on or in connection with a claim were false.
The First Circuit highlighted the difficulties plaintiffs face in overcoming Rule 9(b)’s particularity requirements when using this method to plead an FCA case. In Lawton ex rel. United States v. Takeda Pharm. Co., the relator alleged that the defendant had caused “false” claims to be submitted to the government by third parties as a result of the defendant “engag[ing] in an illegal off-label marketing campaign” for one of its drugs. 842 F.3d 125, 131 (1st Cir. 2016). Because the relator could not demonstrate that any of the particular claims ultimately submitted to the government were actually tainted by this alleged illegal activity, the relator attempted to rely upon statistical evidence that Medicare and Medicaid funds were used to pay for prescriptions of the drug between 2003 and 2012. Id. at 128–32.
The First Circuit rejected relator’s attempts and affirmed dismissal of his claims, holding they were not enough to satisfy even a “flexible” Rule 9(b) pleading standard. The First Circuit stated that although a relator could use “factual or statistical evidence . . . without necessarily providing details as to each [submitted] false claim,” a relator still must identify, among other things, “specific medical providers who allegedly submitted false claims,” the “rough time periods, locations, and amounts of the claims,” and “the specific government programs to which the claims were made.” Id. at 130-31 (emphasis added). The First Circuit concluded that the relator’s statistical evidence in Lawton was not enough to satisfy Rule 9(b) because he merely “point[ed] to the amounts of Medicare and Medicaid funds used to pay for [the] prescriptions” and concluded a “portion of [the] funds must have been used to pay unlawful claims”–saying nothing of who submitted the false claims or when they were submitted. Id. at 132.
Lawton demonstrates that even a nominally “relaxed” Rule 9(b) standard for “statistical evidence” relating to third party submissions of claims remains demanding. Moreover, Lawton makes clear that a relator may not sidestep Rule 9(b)’s requirements that a relator plead the “who, what, when, where, and how of the alleged fraud” simply by pleading statistical evidence. Id. at 130.
Although not in a case involving the pleadings stage, the Fourth Circuit also appeared ready to weigh in on this issue. On October 26, 2016, it heard oral argument in United States ex rel. Michaels v. Agape Senior Community, Inc., No. 15-2145 (4th Cir. 2016). In that case, as we reported in our 2015 Year-End Update, the district court rejected the relators’ request to use statistical sampling to prove liability for the allegedly false claims at issue and to prove damages. The district court found that the case was not suited for sampling because the underlying medical charts for all the claims at issue were “intact and available for review” to determine whether “certain services furnished to nursing home patients were medically necessary.” Michaels, No. 0:12-3466-JFA, 2015 WL 3903675, at *7, *8 (D.S.C. June 25, 2015).
Despite agreeing to hear the issue, the Fourth Circuit indicated during oral argument that it may not ultimately reach the statistical sampling issue, instead ruling on jurisdictional grounds. Oral Arg., Michaels, No. 15-2145 (4th Cir. 2016), http://coop.ca4.uscourts.gov/OAarchive/mp3/15-2145-20161026.mp3. If true, this will come as a disappointment to defendants who had hoped the Fourth Circuit might provide much-needed clarity on the use of statistical sampling in FCA cases.
As we have previously reported, the circuits have in the past split on the proper Rule 9(b) pleading standard for FCA cases. Although the precedents defy easy categorization, generally speaking the Fourth, Eighth, Tenth, and Eleventh Circuits apply a somewhat heightened pleading standard, requiring identification of at least one claim for payment that is false, while several other circuits (including the First, Fifth, Seventh, Ninth, and D.C. Circuits) use a less stringent pleading standard, allowing claims based on allegations of particular details of a scheme to submit false claims paired with reliable indicia that lead to a strong inference that false claims were actually submitted.
The Sixth Circuit recently adopted a relaxed Rule 9(b) pleading standard, at least for certain FCA cases. Over the years, the Sixth Circuit has left open the door for a relaxed pleading standard, and it has now taken at least one step across the threshold with United States ex rel. Prather v. Brookdale Senior Living Communities, Inc., 838 F.3d 750, 773 (6th Cir. 2016). There, the court held that the relator need not identify an actual false claim or produce an actual billing or invoice to survive a motion to dismiss, at least where a relator has “personal billing-related knowledge that support[s] a strong inference that specific false claims were submitted.” Id. at 769, 773. In reaching its decision, the Sixth Circuit explained that a rigid, heightened Rule 9(b) pleading standard would “undermine the effectiveness of the [FCA].” Id. at 772.
The Seventh Circuit also further explored the bounds of its relaxed Rule 9(b) pleading standard. In United States ex rel. Presser v. Acacia Mental Health Clinic, LLC, the Seventh Circuit held that the Rule 9(b) pleading standard may be relaxed even where a relator lacks all the facts necessary to detail her claim. 836 F.3d 770, 778 (7th Cir. 2016). The Seventh Circuit clarified that, although the complaint must provide “plausible” grounds for the relator’s suspicions, a relator’s specific billing knowledge provides enough of an “inference” of fraud to meet the Rule 9(b) pleading requirements even if the relator does not “present, or even include allegations about, a specific document or bill that the defendants submitted to the Government.” Id. at 777–78. To be sure, the Seventh Circuit stated the relaxed standard still requires the relator to demonstrate how the allegedly wrongful scheme could fairly be understood as “unusual” or fraudulent, but it recognized a relator need not identify a specific false claim. Id. at 780.
The FCA’s liability provisions provide that a defendant violates the FCA only if the defendant acts “knowingly.” 31 U.S.C. § 3729(a)(1) (emphasis added).
The Eighth Circuit and Sixth Circuit recently issued opinions relating to the FCA’s scienter standard that are sure to be welcomed by FCA defendants.
For many years, defendants have argued that the FCA’s scienter requirement cannot be met where a false claim is premised on a vague or ambiguous regulatory, statutory, or contractual requirement. These arguments tend to rely on the Supreme Court’s statement in Safeco Ins. Co. Am. v. Burr, 551 U.S. 47, 70 n.20 (2007). Applying another federal statute with a knowledge standard identical to the FCA’s, the Supreme Court held in Safeco that where a statute, regulation, or contract would “allow for more than one reasonable interpretation, it would defy history and current thinking to treat a defendant who merely adopts one such interpretation as a knowing or reckless violator.” See also United States ex rel. Wilson v. Kellogg Brown & Root, Inc., 525 F.3d 370, 378 (4th Cir. 2008) (“An FCA relator cannot base a fraud claim on nothing more than his own interpretation of an imprecise contractual provision.”).
In United States ex rel. Donegan v. Anesthesia Assocs. of Kan. City, PC, the Eighth Circuit held that a defendant’s objectively reasonable interpretation of a government regulation precludes a finding the defendant “knowingly” submitted false claims in violation of this provision. 833 F.3d 874 (8th Cir. 2016). Donegan centered around use of the term “emergence” in a Medicare regulation authorizing reimbursement for anesthesiology services if the physician participated in a patient’s “induction and emergence.” Id. at 879. The Eighth Circuit concluded at the summary judgment stage that the meaning of “emergence” as used in the regulation was “ambiguous” because neither a “controlling source” nor a “professional bod[y]” responsible for “establish[ing] anesthesia standards” had defined the term. Id. at 878. Relying on evidence introduced by the defendant that the defendant had adopted standards defining “emergence” to include treatment administered in the recovery room (bolstered by expert testimony defining the term in the same manner), the Eighth Circuit found the defendant’s interpretation “objectively reasonable.” Id. As a result, it held that a defendant’s “reasonable interpretation of the ambiguous regulation” precluded a finding it knowingly submitted false claims in violation of the FCA. See id. at 880–81.
The Eighth Circuit cautioned, however, that a reasonable interpretation would not necessarily preclude summary judgment on the FCA scienter issue “if a Relator (or the United States) produce[d] sufficient evidence of government guidance that warn[ed] a regulated defendant away from an otherwise reasonable interpretation of an ambiguous regulation.” Id. at 879 (citations and marks omitted) (emphasis in original).
The Eighth Circuit’s decision is notable as it places the burden on the plaintiff to demonstrate the defendant should have adopted a different interpretation of an ambiguous regulation, providing some measure of comfort to FCA defendants that adopt an objectively reasonable interpretation in the face of ambiguous language in a statute or regulation. However, it should be noted that the Eighth Circuit’s decision came at summary judgment, meaning defendants seeking to use its ruling may still be subject to costly discovery.
In United States ex rel. Harper v. Muskingum Watershed, 842 F.3d 430, 436–37 (6th Cir. 2016), the Sixth Circuit demonstrated its willingness to dismiss a case at the pleadings stage on scienter grounds and, in a matter of first impression, opined on the scienter required to state reverse false claims and conversion claims under the FCA.
In 2009, Congress amended the FCA’s reverse false claim provision to impose liability for “knowingly and improperly avoid[ing] or decreas[ing] an obligation to pay or transmit money or property to the Government.” 31 U.S.C. § 3729(a)(1)(G). Construing the term “knowingly,” the Sixth Circuit held that a defendant must both know its conduct violates a legal obligation and must act knowingly, in deliberate ignorance of, or with reckless disregard for the fact that it is involved in conduct that violates a legal obligation to the United States. 842 F.3d at 436–37. Observing that the FCA is not a vehicle to police technical compliance with federal obligations, the Sixth Circuit held that it is not enough for a defendant to know it has a legal obligation but be under the mistaken belief the obligation does not apply. Id. Accordingly, the Sixth Circuit affirmed dismissal of the relator’s complaint under Rule 12(b)(6) for failing to adequately allege the defendant acted with scienter. Id. at 440.
In addition to policing the bounds of “knowing” conduct under the FCA, the Sixth Circuit’s decision also demonstrates that courts can–and should–address scienter issues at the pleadings stage.
As revised by the Affordable Care Act, the FCA’s public disclosure bar provides that a “court [must] dismiss an action or claim . . . if substantially the same allegations or transactions . . . were publicly disclosed” in a prior case or via the news media “unless . . . the person bringing the action is an original source of the information.” 31 U.S.C. § 3730 (e)(4)(A)(i)-(iii).
Congress amended the FCA in 2010 to provide that an “original source” is someone who either “(1) prior to a public disclosure . . . has voluntarily disclosed to the Government the information on which allegations or transactions in a claim are based, or (2) who has knowledge that is independent of and materially adds to the publicly disclosed allegations or transactions.” 31 U.S.C. § 3730(e)(4)(B) (2010). Prior to this, the statute allowed a relator to qualify as an original source only if he or she possessed “direct and independent knowledge” of the alleged fraud. See 31 U.S.C. § 3730(e)(4)(B) (1986).
Two decisions addressing original source status under the FCA reinforce the notion that relators face a high burden under either version of the FCA’s public disclosure bar when the underlying allegations have been publicly disclosed.
In United States Hastings v. Wells Fargo Bank, NA, the Ninth Circuit held the relator was not an original source under either the current or pre-2010 version of the FCA’s public disclosure bar. 656 F. App’x 328, 330 (9th Cir. 2016). Under the pre-2010 version, the Ninth Circuit held the relator lacked “direct” knowledge of the purported insurance fraud at issue because he relied on evidence such as real estate postings, internal lending guidelines, and other public documents rather than anything demonstrating he “[saw] the fraud with [his] own eyes” to reach his conclusions. Id. at 331. The relator also failed to qualify as an original source under the current FCA. Id. Among other reasons, the relator’s knowledge provided “only background information and details relating to the alleged fraud” and thus did not “materially add to [the] public disclosure” as required by the statute. Id. at 331–32. For instance, the relator had argued he was an original source based on letters he sent to the government, but the Ninth Circuit found those letters “consisted of speculation rather than knowledge” and merely described the government “program in general [terms] and the possibility that it would” be fraudulently misused rather than the key facts of the alleged fraud. Id. at 330–31. To the extent the letters contained facts relating to the fraud, the Ninth Circuit found that the government already “knew” that information because it had obtained the facts in connection with an earlier related settlement. Id. at 331–32.
The Eleventh Circuit in November also addressed “whether [the relator’s] secondhand knowledge is sufficient to make him an original source” under the pre-2010 version of the FCA’s public disclosure bar, joining the Third, Seventh, Eighth, and Tenth Circuits in finding that it does not. United States ex rel. Saldivar v. Fresenius Med. Care Holdings, Inc., 841 F.3d 927, 935 (11th Cir. 2016).
In Saldivar, the relator filed suit claiming the defendant had billed the government for drug “overfill” (an amount in excess of what was indicated on the drug’s labeling) that it received at no cost. Id. Although the relator had “firsthand knowledge related to inventory and administration of overfill,” the Eleventh Circuit found he had only “secondhand knowledge” related to the alleged improper billing of the government (i.e., the FCA violation itself) because he had only ever “heard about [the] billing practice from others” rather than directly observing it himself. Id. at 936. The Eleventh Circuit held such secondhand knowledge was insufficient to meet the “direct” knowledge requirement in the pre-2010 version of the public disclosure bar. Id. at 937.
In the latest ruling in a long-running FCA saga we have covered in the past, the Fourth Circuit addressed the proper test for determining liability of a successor corporation in FCA cases. The dispute in United States ex rel. Bunk v. Government Logistics N.V. began more than 15 years ago and previously resulted in the Fourth Circuit ruling that a $24 million judgment should be entered in the relator’s favor against Gosselin, one of the corporate defendants. 842 F.3d 261, 273–74 (4th Cir. 2016).
In the Fourth Circuit’s most recent opinion in the case, relator Bunk attempted to recover his judgment from an alleged successor corporation to the Gosselin defendant. Although the Fourth Circuit ultimately found the relator could take advantage of an exception for fraudulent mergers to attempt to obtain judgment from Gosselin’s successor, it rejected application of a relaxed standard for determining successor liability in the FCA context. Id. at 273–74. The Fourth Circuit held that because the FCA did not specifically address the rule for successor liability, courts should apply the common law test, which looks to whether the successor is a “mere continuation” of the prior entity and impose successor liability only in those circumstances (or where another narrow exception might apply). Id. at 274.
Under the FCA’s anti-retaliation provision, an employer may not “discharge, demote, suspend, threaten, harass, or in any manner discriminate against [an employee or contractor] because of  lawful acts done by [the employee or contractor] . . . in furtherance of an action under [the FCA] or  other efforts to stop 1 or more violations of [the Act].” 31 U.S.C. § 3730(h)(1).
Two circuits recently provided guidance on what standards lower courts should apply in assessing a retaliation claim under the FCA.
In Carlson v. DynCorp International LLC, the Fourth Circuit became one of the first to address the expanded protections Congress afforded to whistleblowers in anti-retaliation provisions in the 2010 amendments to the FCA. 657 F. App’x 168 (4th Cir. 2016). In Carlson, the defendant allegedly terminated the plaintiff for questioning his employer’s billing practices, which resulted in underbilling of the government. Id. at 169. The plaintiff argued that this conduct “amounted to ‘efforts to stop 1 or more violations of [the FCA]'” pursuant to Section 3730(h)(1). Id. at 170.
The district court, in granting a motion to dismiss, applied the “distinct possibility” test, which provides that “an employee engages in protected activity [under Section 3730(h)] when litigation is a distinct possibility, when the conduct reasonably could lead to a viable FCA action, or . . . when litigation is a reasonable possibility.” Id. at 171 (citations omitted) (internal quotation marks omitted). The Fourth Circuit found the district court’s articulation of law was error, explaining that the district court’s announced test only applies when an employee engages in protected activity under the first prong of Section 3730(h)(1)–“lawful acts done . . . in furtherance of an action under [the FCA].” Id. at 171–72. The Fourth Circuit noted that Congress had expanded the scope of the FCA’s anti-retaliation provision in 2010 to include additional protection for “efforts to stop 1 or more violations of [the FCA].” Id. The Fourth Circuit concluded that the “distinct possibility” test did not apply to the “efforts to stop” prong. Id. Instead, the Fourth Circuit “assume[d], without deciding” that an employee engages in protected activity under this other prong when his “efforts are motivated by an objectively reasonable belief that the . . . employer is violating, or soon will violate, the FCA.” Id. at 172. The Fourth Circuit affirmed dismissal of the relator’s claim here, concluding “his alleged belief that [his employer] was violating the FCA was not reasonable” because the plaintiff could not “point to any . . . provision or case that would make under billing a violation [of the FCA],” as the statute is only concerned with financial loss to the government Id. at 173–75.
The Seventh Circuit recently provided guidance on what constitutes protected activity under the first prong of Section 3730(h)(1) in United States ex rel. Uhlig v. Fluor Corp., 839 F.3d 628, 635 (7th Cir. 2016). There, the plaintiff claimed the defendant was employing unlicensed electricians in violation of a government contract and reported the information to the government as well as a whistleblower website. Id. at 633. The plaintiff was later terminated for including confidential information in his e-mail to the website, in violation of the employer’s computer-use policy. Id. He claimed his discharge was unlawful retaliation under the first prong of Section 3730(h)(1). See id. at 635 (citations omitted).
To determine whether the plaintiff engaged in protected activity under the statute, the Seventh Circuit applied a two-prong test: “whether (1) the employee in good faith believes, and (2) a reasonable employee in the same or similar circumstances might believe, that the employer is committing fraud against the government.” Id. In other words, the plaintiff must both subjectively and objectively believe the employer is violating the FCA. The Seventh Circuit held that the plaintiff failed the objective prong of the test because he lacked “firsthand knowledge” of the purported fraud and what he did know “was not sufficient to cause a reasonable person to suspect fraud on the part of [the defendant].” Id.
Carlson and Uhlig demonstrate that a plaintiff must have an “objectively reasonable” basis for asserting the defendant was committing a fraud on the government in violation of the FCA for a retaliation claim to pass muster under Section 3730(h)(1).
The coming year can credibly promise several things: a new administration, including new DOJ political appointees, and additional jurisprudence interpreting the scope of Escobar. We will report back to you on the news in early July–and, in the meantime, continue our work with many of you to shape developments in the FCA space.
 See Press Release, Office of Pub. Affairs, U.S. Dep’t of Justice, Justice Department Recovers Over $4.7 Billion from False Claims Act Cases in Fiscal Year 2016 (Dec. 14, 2016), https://www.justice.gov/opa/pr/justice-department-recovers-over-47-billion-false-claims-act-cases-fiscal-year-2016 [hereinafter DOJ FY 2016 Recoveries Press Release].
 Id.; see also Fraud Statistics Overview (Dec. 13, 2016), https://www.justice.gov/opa/press-release/file/918361/download [hereinafter DOJ FY 2016 Stats].
 See Press Release, Office of Pub. Affairs, U.S. Dep’t of Justice, Acting Assistant Attorney General Stuart F. Delery Speaks at the American Bar Association’s Ninth National Institute on the Civil False Claims Act and Qui Tam Enforcement (June 7, 2012), http://www.justice.gov/iso/opa/civil/speeches/2012/civ-speech-1206071.html.
 See Press Release, Office of Pub. Affairs, U.S. Dep’t of Justice, Wyeth and Pfizer Agree to Pay $784.6 Million to Resolve Lawsuit Alleging That Wyeth Underpaid Drug Rebates to Medicaid (Apr. 27, 2016), https://www.justice.gov/opa/pr/wyeth-and-pfizer-agree-pay-7846-million-resolve-lawsuit-alleging-wyeth-underpaid-drug-rebates.
 See Press Release, U.S. Atty’s Office for the Southern Dist. of N.Y., U.S. Dep’t of Justice, Manhattan U.S. Attorney Announces $370 Million Civil Fraud Settlement Against Novartis Pharmaceuticals For Kickback Scheme Involving High-Priced Prescription Drugs, Along With $20 Million Forfeiture Of Proceeds From The Scheme (Nov. 20, 2015), https://www.justice.gov/usao-sdny/pr/manhattan-us-attorney-announces-370-million-civil-fraud-settlement-against-novartis.
 See U.S. Dep’t of Health & Human Services, Office of Inspector Gen., Semiannual Report to Congress (October 1, 2015 – March 31, 2016) at 12, https://oig.hhs.gov/reports-and-publications/archives/semiannual/2016/SAR_Spring_2016.pdf.
 See U.S. Dep’t of Health & Human Services, Office of Inspector Gen., Semiannual Report to Congress (October 1, 2014 – March 31, 2015) at 15, http://oig.hhs.gov/reports-and-publications/archives/semiannual/2015/sar-spring15.pdf.
 See U.S. Dep’t of Health & Human Services, Office of Inspector Gen., Semiannual Report to Congress (October 1, 2015 – March 31, 2016) at iv, https://oig.hhs.gov/reports-and-publications/archives/semiannual/2016/SAR_Spring_2016.pdf.
 See U.S. Dep’t of Health & Human Services, Office of Inspector Gen., Semiannual Report to Congress (October 1, 2014 – March 31, 2015) at 15 (reporting expected recoveries of approximately $1.8 billion, including about $1.26 billion in “investigative receivables”), http://oig.hhs.gov/reports-and-publications/archives/semiannual/2015/sar-spring15.pdf.
 See Press Release, Office of Pub. Affairs, U.S. Dep’t of Justice, Millennium Health Agrees to Pay $256 Million to Resolve Allegations of Unnecessary Drug and Genetic Testing and Illegal Remuneration to Physicians (Oct. 19, 2015), https://www.justice.gov/opa/pr/millennium-health-agrees-pay-256-million-resolve-allegations-unnecessary-drug-and-genetic.
 See Press Release, Office of Pub. Affairs, U.S. Dep’t of Justice, Hospital Chain Will Pay over $513 Million for Defrauding the United States and Making Illegal Payments in Exchange for Patient Referrals; Two Subsidiaries Agree to Plead Guilty (Oct. 3, 2016), https://www.justice.gov/opa/pr/hospital-chain-will-pay-over-513-million-defrauding-united-states-and-making-illegal-payments.
 See Press Release, Office of Pub. Affairs, U.S. Dep’t of Justice, Texas-Based Importers Agree to Pay $15 Million to Settle False Claims Act Suit for Alleged Evasion of Customs Duties (Dec. 21, 2015), https://www.justice.gov/opa/pr/texas-based-importers-agree-pay-15-million-settle-false-claims-act-suit-alleged-evasion; Press Release, Office of Pub. Affairs, U.S. Dep’t of Justice, California-Based Z Gallerie LLC Agrees to Pay $15 Million to Settle False Claims Act Suit Alleging Evaded Customs Duties (Apr. 27, 2016), https://www.justice.gov/opa/pr/california-based-z-gallerie-llc-agrees-pay-15-million-settle-false-claims-act-suit-alleging.
 See Press Release, U.S. Atty’s Office for the Western Dist. of N.C., U.S. Dep’t of Justice, Medical Device Company Agrees To Pay $8 Million To Resolve Claims It Paid Illegal Kickbacks To Physicians (June 29, 2016), https://www.justice.gov/usao-wdnc/pr/medical-device-company-agrees-pay-8-million-resolve-claims-it-paid-illegal-kickbacks.
 See Press Release, U.S. Atty’s Office for the Eastern Dist. of Cal., U.S. Dep’t of Justice, El Dorado County Health Care Provider Agrees to Pay $5.5m to Resolve False Claims Act Allegations (June 30, 2016), https://www.justice.gov/usao-edca/pr/el-dorado-county-health-care-provider-agrees-pay-55m-resolve-false-claims-act.
 See Press Release, U.S. Atty’s Office for the Dist. of S.C., U.S. Dep’t of Justice, Drayer Physical Therapy Institute, LLC Settle False Claims Act Case for $7,000,000 (July 5, 2016), https://www.justice.gov/usao-sc/pr/drayer-physical-therapy-institute-llc-settle-false-claims-act-case-7000000.
 See Press Release, Off. of Pub. Affairs, U.S. Dep’t of Justice, Minnesota-Based Hospice Provider to Pay $18 Million for Alleged False Claims to Medicare for Patients Who Were Not Terminally Ill (July 13, 2016), https://www.justice.gov/opa/pr/minnesota-based-hospice-provider-pay-18-million-alleged-false-claims-medicare-patients-who.
 See Press Release, U.S. Atty’s Office for the Eastern Dist. of N.J., U.S. Dep’t of Justice, New Jersey Couple And Two Diagnostic Companies Ordered To Pay $7.75 Million For Falsifying Diagnostic Test Reports And Failing To Properly Supervise Tests (July 12, 2016), https://www.justice.gov/usao-nj/pr/new-jersey-couple-and-two-diagnostic-companies-ordered-pay-775-million-falsifying.
 See Press Release, U.S. Atty’s Office for the Eastern Dist. of Ky., U.S. Dep’t of Justice, U.S. District Court Orders $4.5 Million Civil Judgment Against Lexington Woman And Her Medical Device Companies For Committing Grant Fraud (July 13, 2016), https://www.justice.gov/usao-edky/pr/us-district-court-orders-45-million-civil-judgment-against-lexington-woman-and-her.
 See Press Release, U.S. Atty’s Office for the Northern Dist of Tex., U.S. Dep’t of Justice, Prefered Imaging, LLC to Pay $3,510,000 to Resolve False Claims Act Allegations (July 22, 2016), https://www.justice.gov/usao-ndtx/pr/prefered-imaging-llc-pay-3510000-resolve-false-claims-act-allegations.
 See Press Release, Office of Pub. Affairs, U.S. Dep’t of Justice, Johnson & Johnson Subsidiary Acclarent Inc. Pays Government $18 Million to Settle False Claims Act Allegations (July 22, 2016), https://www.justice.gov/opa/pr/johnson-johnson-subsidiary-acclarent-inc-pays-government-18-million-settle-false-claims-act.
 See Press Release, Office of Pub. Affairs, U.S. Dep’t of Justice, South Carolina Hospital to Pay $17 Million to Resolve False Claims Act and Stark Law Allegations (July 28, 2016), https://www.justice.gov/opa/pr/south-carolina-hospital-pay-17-million-resolve-false-claims-act-and-stark-law-allegations.
 See Press Release, U.S. Atty’s Office for the Western Dist. of Okla., U.S. Dep’t of Justice, United States and State Of Oklahoma Obtain $4.7 Million Judgment Against Behavioral Health Counseling Company and Its Owner for Submitting False Claims (July 29, 2016), https://www.justice.gov/usao-wdok/pr/united-states-and-state-oklahoma-obtain-47-million-judgment-against-behavioral-health.
 See Press Release, U.S. Atty’s Office for the Northern Dist. of N.Y., U.S. Dep’t of Justice, St. Joseph’s Hospital To Pay $3.2 Million For Billing MEDICAID For Mental Health Services Rendered By Unqualified Staff (August 1, 2016), https://www.justice.gov/usao-ndny/pr/st-joseph-s-hospital-pay-32-million-billing-medicaid-mental-health-services-rendered.
 See Press Release, U.S. Atty’s Office for the Middle Dist. of Fla., U.S. Dep’t of Justice, United States Settles False Claims Act Allegations Against Coastal Spine And Pain For $7.4 Million (Aug. 31, 2016), https://www.justice.gov/usao-mdfl/pr/united-states-settles-false-claims-act-allegations-against-coastal-spine-and-pain-74.
 See Press Release, Office of Public Affairs, U.S. Dep’t of Justice, Diabetic Medical Equipment Companies to Pay More Than $12 Million to Resolve False Claims Act Allegations (Sept. 7, 2016), https://www.justice.gov/opa/pr/diabetic-medical-equipment-companies-pay-more-12-million-resolve-false-claims-act-allegations.
 See Press Release, U.S. Atty’s Office for the Northern Dist. of Ill., U.S. Dep’t of Justice, Owner of Illinois Home Health Company Admits Paying Illegal Kickbacks to 20 Medical Directors for Referrals of Medicare Patients (Sept. 14, 2016), https://www.justice.gov/usao-ndil/pr/owner-illinois-home-health-company-admits-paying-illegal-kickbacks-20-medical-directors.
 See Press Release, U.S. Atty’s Office for the Middle Dist. of Fla., U.S. Dep’t of Justice, United States Settles False Claims Act Allegations Against Compound Pharmacy Owners For $7.75 Million (Sept. 14, 2016), https://www.justice.gov/usao-mdfl/pr/united-states-settles-false-claims-act-allegations-against-compound-pharmacy-owners-775.
 See Press Release, Office of Pub. Affairs, U.S. Dep’t of Justice, North American Health Care Inc. to Pay $28.5 Million to Settle Claims for Medically Unnecessary Rehabilitation Therapy Services (Sept. 19, 2016), https://www.justice.gov/opa/pr/north-american-health-care-inc-pay-285-million-settle-claims-medically-unnecessary.
 See Press Release, Office of Pub. Affairs, U.S. Dep’t of Justice, Vibra Healthcare to Pay $32.7 Million to Resolve Claims for Medically Unnecessary Services (Sept. 28, 2016), https://www.justice.gov/opa/pr/vibra-healthcare-pay-327-million-resolve-claims-medically-unnecessary-services.
 See Press Release, U.S. Atty’s Office for the Northern Dist. Home Health Care Agency Ordered to Pay Over $6 Million For False Claims Made to D.C. Medicaid (Sept. 30, 2016), https://www.justice.gov/usao-dc/pr/home-health-care-agency-ordered-pay-over-6-million-false-claims-made-dc-medicaid.
 See Press Release, Office of Pub. Affairs, U.S. Dep’t of Justice, Hospital Chain Will Pay over $513 Million for Defrauding the United States and Making Illegal Payments in Exchange for Patient Referrals; Two Subsidiaries Agree to Plead Guilty (Oct. 3, 2016), https://www.justice.gov/opa/pr/hospital-chain-will-pay-over-513-million-defrauding-united-states-and-making-illegal-payments.
 See Press Release, U.S. Atty’s Office for the Western Dist. of Wash., Nutritional Supplement Provider and CEO Plead Guilty & Agree to Pay Over $6.1 Million to Resolve False Claims Act Allegations (Oct. 14, 2016), https://www.justice.gov/usao-wdwi/pr/nutritional-supplement-provider-and-ceo-plead-guilty-false-claims-act-violations.
 See Press Release, U.S. Atty’s Office for the Dist. of Ariz., Yavapai Regional Medical Center to Pay $5.85 Million to Resolve False Claims Allegations (Oct. 14, 2016), https://www.justice.gov/usao-az/pr/yavapai-regional-medical-center-pay-585-million-resolve-false-claims-allegations.
 See Press Release, Office of Pub. Affairs, U.S. Dep’t of Justice, Nation’s Largest Nursing Home Pharmacy to Pay Over $28 Million to Settle Kickback Allegations (Oct. 17, 2016), https://www.justice.gov/opa/pr/nation-s-largest-nursing-home-pharmacy-pay-over-28-million-settle-kickback-allegations.
 See Press Release, U.S. Atty’s Office for the Southern Dist. of N.Y., Manhattan U.S. Attorney Announces $5.31 Million Civil Settlement Against Hematology-Oncology Medical Practice For Submitting False Claims To Medicare And Medicaid (Oct. 21, 2016), https://www.justice.gov/usao-sdny/pr/manhattan-us-attorney-announces-531-million-civil-settlement-against-hematology.
 See Press Release, U.S. Atty’s Office for the Middle Dist. of Fla., United States Settles False Claims Act Allegations Against Compound Pharmacy Owner For $4.25 Million (Oct. 21, 2016), https://www.justice.gov/usao-mdfl/pr/united-states-settles-false-claims-act-allegations-against-compound-pharmacy-owner-425.
 See Press Release, Office of Pub. Affairs, U.S. Dep’t of Justice, Life Care Centers of America Inc. Agrees to Pay $145 Million to Resolve False Claims Act Allegations Relating to the Provision of Medically Unnecessary Rehabilitation Therapy Services (Oct. 24, 2016), https://www.justice.gov/opa/pr/life-care-centers-america-inc-agrees-pay-145-million-resolve-false-claims-act-allegations.
 See Press Release, U.S. Atty’s Office for the Northern Dist. of Tex., U.S. Dep’t of Justice, Nursing Home Chain to Pay $5.3 Million to Resolve False Claims Act Allegations (Oct. 24, 2016), https://www.justice.gov/usao-ndtx/pr/nursing-home-chain-pay-53-million-resolve-false-claims-act-allegations.
 See Press Release, Office of Pub. Affairs, U.S. Dep’t of Justice, Medical Device Maker Biocompatibles Pleads Guilty to Misbranding and Agrees to Pay $36 Million to Resolve Criminal Liability and False Claims Act Allegations (Nov. 7, 2016), https://www.justice.gov/opa/pr/medical-device-maker-biocompatibles-pleads-guilty-misbranding-and-agrees-pay-36-million.
 See Press Release, U.S. Atty’s Office for the Middle Dist. of Fla., United States Settles False Claims Act Allegations Against Orthopedic Surgery Practice For $4,488,000 (Dec. 7, 2016), https://www.justice.gov/usao-mdfl/pr/united-states-settles-false-claims-act-allegations-against-orthopedic-surgery-practice.
 See Press Release, U.S. Atty’s Office for the Southern Dist. of Fla., South Miami Hospital Agrees to Pay the United States $12 Million to Settle False Claims Act Allegations (Dec. 7, 2016), https://www.justice.gov/usao-sdfl/pr/south-miami-hospital-agrees-pay-united-states-12-million-settle-false-claims-act.
 See Press Release, Office of the Att’y Gen. of Tex., AG Paxton: Texas and 42 States Reach $19.5 Million Settlement with Bristol-Myers Squibb Company (Dec. 8, 2016), https://texasattorneygeneral.gov/news/releases/ag-paxton-texas-and-42-states-reach-19.5-million-settlement-with-bristol-my.
 See Press Release, Office of Pub. Affairs, U.S. Dep’t of Justice, Forest Laboratories and Forest Pharmaceuticals to Pay $38 million to Resolve Kickback Allegations Under the False Claims Act (Dec. 15, 2016), https://www.justice.gov/opa/pr/forest-laboratories-and-forest-pharmaceuticals-pay-38-million-resolve-kickback-allegations?_ga=1.182418405.375859627.1482512127.
 See Press Release, U.S. Atty’s Office for the Central Dist. of Cal., U.S. Dep’t of Justice, Information Technology Companies to Pay $5.8 Million for Misrepresentations Relating to Small Business Status and Contract Fee Payments (July 6, 2016), https://www.justice.gov/usao-cdca/pr/information-technology-companies-pay-58-million-misrepresentations-relating-small.
 See Press Release, U.S. Atty’s Office for the Southern Dist. of N.Y., U.S. Dep’t of Justice, Manhattan U.S. Attorney Announces $9.5 Million Settlement With Columbia University For Improperly Seeking Excessive Cost Recoveries In Connection With Federal Research Grants (July 14, 2016), https://www.justice.gov/usao-sdny/pr/manhattan-us-attorney-announces-95-million-settlement-columbia-university-improperly.
 See Press Release, U.S. Atty’s Office for the Dist. of Nev., Reno Geothermal Power Plant Operator Enters Into $5.5 Million Settlement With DOJ Over Grant Fraud Allegations (Oct. 28, 2016), https://www.justice.gov/usao-nv/pr/reno-geothermal-power-plant-operator-enters-55-million-settlement-doj-over-grant-fraud.
 See Press Release, U.S. Atty’s Office for the Central Dist. of Cal., Aerospace Parts Manufacturer Pays $2.7 Million to Settle Lawsuit Alleging it Failed to Perform Required Inspections on Parts (Nov. 4, 2016), https://www.justice.gov/usao-cdca/pr/aerospace-parts-manufacturer-pays-27-million-settle-lawsuit-alleging-it-failed-perform.
 See Press Release, Office of Pub. Affairs, U.S. Dep’t of Justice, United States Settles Lawsuit Against Energy Department Contractors for Knowingly Mischarging Costs on Contract at Nuclear Waste Treatment Plant (Nov. 23, 2016), https://www.justice.gov/opa/pr/united-states-settles-lawsuit-against-energy-department-contractors-knowingly-mischarging.
 See Press Release, U.S. Atty’s Office for the Dist. of Md., U.S. Dep’t of Justice, PNC Bank to Pay $9.5 Million for Failing to Engage in Prudent Underwriting Practices for Loans Guaranteed by the U.S. Small Business Administration (Aug. 16, 2016), https://www.justice.gov/usao-md/pr/pnc-bank-pay-95-million-failing-engage-prudent-underwriting-practices-loans-guaranteed-us.
 See Press Release, Office of Public Affairs, U.S. Dep’t of Justice, Regions Bank Agrees to Pay $52.4 Million to Resolve Alleged False Claims Act Liability Arising from FHA-Insured Mortgage Lending (Sept. 13, 2016), https://www.justice.gov/opa/pr/regions-bank-agrees-pay-524-million-resolve-alleged-false-claims-act-liability-arising-fha.
 See Press Release, Office of Pub. Affairs, U.S. Dep’t of Justice, Branch Banking & Trust Company Agrees to Pay $83 Million to Resolve Alleged False Claims Act Liability Arising from FHA-Insured Mortgage Lending (Sept. 29, 2016), https://www.justice.gov/opa/pr/branch-banking-trust-company-agrees-pay-83-million-resolve-alleged-false-claims-act-liability.
 See Press Release, Office of Pub. Affairs, U.S. Dep’t of Justice, Utah-Based Lenders Agree to Pay Nearly $10 Million to Resolve Alleged False Claims Act Liability Arising from FHA-Insured Mortgage Lending (Oct. 3, 2016), https://www.justice.gov/opa/pr/utah-based-lenders-agree-pay-nearly-10-million-resolve-alleged-false-claims-act-liability.
 See Press Release, U.S. Atty’s Office for the S. Dist. of Tex., U.S. Dep’t of Justice, Jury Finds Allied Home Mortgage Entities and CEO Liable for Civil Mortgage Fraud – Awards $92 Million in Damages (Nov. 30, 2016), https://www.justice.gov/usao-sdtx/pr/jury-finds-allied-home-mortgage-entities-and-ceo-liable-civil-mortgage-fraud-awards-92.
 See Press Release, U.S. Atty’s Office for the Southern Dist. of N.Y., Dep’t of Justice, Manhattan U.S. Attorney Settles Civil Fraud Lawsuit Against Clothing Importer And Manufacturers For Evading Customs Duties (July 13, 2016), https://www.justice.gov/usao-sdny/pr/manhattan-us-attorney-settles-civil-fraud-lawsuit-against-clothing-importer-and.
 See Press Release, U.S. Atty’s Office for the Southern Dist. of N.Y., U.S. Dep’t of Justice, Manhattan U.S. Attorney Announces Settlements Totaling $4.29 Million With For-Profit School And Its Former Chief Operating Officer (July 14, 2016), https://www.justice.gov/usao-sdny/pr/manhattan-us-attorney-announces-settlements-totaling-429-million-profit-school-and-its.
 See Press Release, U.S. Atty’s Office for the Central Dist. of Cal., U.S. Dep’t of Justice, Defunct Cosmetology School’s Insurer Pays $8.6 Million to Resolve Claims that School Improperly Obtained Federal Student Loan Funds (Aug. 24, 2016), https://www.justice.gov/usao-cdca/pr/defunct-cosmetology-school-s-insurer-pays-86-million-resolve-claims-school-improperly.
 Civil Monetary Penalties Inflation Adjustment, 81 Fed. Reg. 42,500–42,5011 (June 30, 2016), https://www.gpo.gov/fdsys/pkg/FR-2016-06-30/pdf/2016-15528.pdf.
 Amita Kelly & Barbara Sprunt, Here is What Donald Trump Wants To Do In His First 100 Days, NPR.org (Nov. 9, 2016, 3:45 PM) http://www.npr.org/2016/11/09/501451368/here-is-what-donald-trump-wants-to-do-in-his-first-100-days.
 See U.S. Dep’t of Health & Human Servs., Office of Inspector Gen., State False Claims Act Reviews, https://oig.hhs.gov/fraud/state-false-claims-act-reviews/index.asp.
 S.B. 327, 2016 Reg. Sess. (La. 2016), http://www.legis.la.gov/legis/BillInfo.aspx?s=16RS&b=SB327&sbi=y.
 See Letter from Daniel R. Levinson, Inspector Gen., U.S. Dep’t of Health & Human Servs., to Att’y Gen. Adam Paul Laxalt (May 6, 2016), https://oig.hhs.gov/fraud/docs/falseclaimsact/Nevada.pdf.
 See Letter from Daniel R. Levinson, Inspector Gen., U.S. Dep’t of Health & Human Servs., to Att’y Gen. Bob Ferguson (June 30, 2016), https://oig.hhs.gov/fraud/docs/falseclaimsact/Washington.pdf.
 See U.S. Dep’t of Health & Human Servs., Office of Inspector Gen., State False Claims Act Reviews, https://oig.hhs.gov/fraud/state-false-claims-act-reviews/index.asp.
 S.B. 216, 2016 Reg. Sess. (Ala. 2016), https://legiscan.com/AL/bill/SB216/2016.
 S.B. 2645, 216th Leg. (N.J. 2015); S.B. 326, 217th Leg. (N.J. 2016), http://www.njleg.state.nj.us/bills/BillView.asp?BillNumber=S326.
 B. A07304, 238th Leg. (N.Y. 2015), http://assembly.state.ny.us/leg/?default_fld=&bn=A07304&term=2015&Summary=Y&Text=Y.
 2015 S.C. S.B. 223, South Carolina General Assembly 121st Session 2015-2016, http://www.scstatehouse.gov/sess121_2015-2016/bills/223.htm.
 United States ex rel. Joshi v. St. Luke’s Hosp., Inc., 441 F.3d 552, 557 (8th Cir. 2006) (requiring detailed allegations of at least some examples of allegedly fraudulent conduct), cert. denied, 549 U.S. 881 (2006); United States ex rel. Sikkenga v. Regence Bluecross Blueshield of Utah, 472 F.3d 702, 727 (10th Cir. 2006) (same); United States ex rel. Clausen v. Laboratory Corp. of Am., Inc., 290 F.3d 1301, 1311 (11th 2002) (same), cert. denied, 537 U.S. 1105 (2003); United States ex rel. Nathan v. Takeda Pharms., 707 F.3d 451, 456-57 (4th Cir. 2013), cert. denied, 134 S. Ct. 1759 (2014).
 Ebeid ex rel. United States v. Lungwitz, 616 F.3d 993, 998–99 (9th Cir.) (allowing claims based on allegations of “particular details of a scheme to submit false claims paired with reliable indicia that lead to a strong inference that claims were actually submitted”), cert. denied, 562 U.S. 1102 (2010); Foglia v. Renal Ventures Mgmt., LLC, 754 F.3d 153, 155–56 (3d Cir. 2014) (same); United States ex rel. Grubbs v. Kanneganti, 565 F.3d 180, 190–91 (5th Cir. 2009) (same); United States ex rel. Duxbury v. Ortho Biotech Prods. L.P., 579 F.3d 13, 29 (1st Cir. 2009) (holding that, in actions “in which the defendant induced third parties to file false claims with the government,” it was not necessary to “provid[e] details as to each false claim” if there was “factual or statistical evidence to strengthen the inference of fraud beyond possibility” (emphasis in original)), cert. denied, 561 U.S. 1005, (2010); United States ex rel. Lusby v. Rolls–Royce Corp., 570 F.3d 849, 854–55 (7th Cir. 2009) (“It is enough to show, in detail, the nature of the charge, so that vague and unsubstantiated accusations of fraud do not lead to costly discovery and public obloquy.”); United States ex rel. Heath v. AT&T, Inc., 791 F.3d 112, 126 (D.C. Cir. 2015) (same), cert. denied, 136 S. Ct. 2505 (2016).
The following Gibson Dunn lawyers assisted in preparing this client update: F. Joseph Warin, Robert Blume, Timothy Hatch, Stephen Payne, Alexander Southwell, Charles Stevens, Joseph West, John Partridge, James Zelenay, Jonathan Phillips, Jeremy Ochsenbein, Sean Twomey, Reid Rector, Allison Chapin, Yamini Grema, Eva Michaels, Mary Kwon, Jason Kim, Jacob Rierson, Meghan Dunn, Justin Epner and Ryan Bergsieker.
Gibson Dunn’s lawyers have handled hundreds of FCA investigations and have a long track record of litigation success. Among other significant victories, Gibson Dunn successfully argued the landmark Allison Engine case in the Supreme Court, a unanimous decision that prompted Congressional action. See Allison Engine Co. v. United States ex rel. Sanders, 128 S. Ct. 2123 (2008). Our win rate and immersion in FCA issues gives us the ability to frame strategies to quickly dispose of FCA cases. The firm has more than 30 attorneys with substantive FCA expertise and more than 30 former Assistant U.S. Attorneys and DOJ attorneys. For more information, please feel free to contact the Gibson Dunn attorney with whom you work or the following attorneys.
F. Joseph Warin (+1 202-887-3609, [email protected])
Joseph D. West (+1 202-955-8658, [email protected])
Andrew S. Tulumello (+1 202-955-8657, [email protected])
Karen L. Manos (+1 202-955-8536, [email protected])
Stephen C. Payne (+1 202-887-3693, [email protected])
Jonathan M. Phillips (+1 202-887-3546, [email protected])
Robert C. Blume (+1 303-298-5758, [email protected])
Monica K. Loseman (+1 303-298-5784, [email protected])
John D.W. Partridge (+1 303-298-5931, [email protected])
Ryan T. Bergsieker (+1 303-298-5774, [email protected])
Nicola T. Hanna (+1 949-451-4270, [email protected])
© 2017 Gibson, Dunn & Crutcher LLP
Attorney Advertising: The enclosed materials have been prepared for general informational purposes only and are not intended as legal advice.